Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENALUT: 177Lu-PSMA in metastatic clear cell renal cell carcinoma
2024-517899-38-00Phase 2Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in clear cell renal cell carcinoma (ccRCC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective Response Rate (ORR). Planned start Feb 2026; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2024-517899-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517899-38-00.